Menu Search
Equities

Spero Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2HA:DUS

Spero Therapeutics Inc

Actions
  • Price (EUR)2.00
  • Today's Change0.054 / 2.77%
  • Shares traded2.35k
  • 1 Year change+143.90%
  • Beta1.4318
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

  • Revenue in USD (TTM)40.55m
  • Net income in USD-43.84m
  • Incorporated2013
  • Employees32.00
  • Location
    Spero Therapeutics Inc675 Massachusetts Ave Ste 14CAMBRIDGE 02139-3309United StatesUSA
  • Phone+1 (857) 242-1600
  • Fax+1 (302) 655-5049
  • Websitehttps://sperotherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.